GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provectus Biopharmaceuticals Inc (OTCPK:PVCT) » Definitions » Current Ratio

Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Current Ratio : 0.12 (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Provectus Biopharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Provectus Biopharmaceuticals's current ratio for the quarter that ended in Mar. 2024 was 0.12.

Provectus Biopharmaceuticals has a current ratio of 0.12. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Provectus Biopharmaceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Provectus Biopharmaceuticals's Current Ratio or its related term are showing as below:

PVCT' s Current Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.27   Max: 24.8
Current: 0.12

During the past 13 years, Provectus Biopharmaceuticals's highest Current Ratio was 24.80. The lowest was 0.01. And the median was 0.27.

PVCT's Current Ratio is ranked worse than
96.05% of 1544 companies
in the Biotechnology industry
Industry Median: 3.785 vs PVCT: 0.12

Provectus Biopharmaceuticals Current Ratio Historical Data

The historical data trend for Provectus Biopharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provectus Biopharmaceuticals Current Ratio Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.01 0.45 0.23 0.15

Provectus Biopharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.18 0.17 0.15 0.12

Competitive Comparison of Provectus Biopharmaceuticals's Current Ratio

For the Biotechnology subindustry, Provectus Biopharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provectus Biopharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's Current Ratio falls into.



Provectus Biopharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Provectus Biopharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=1.365/9.017
=0.15

Provectus Biopharmaceuticals's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )=Total Current Assets (Q: Mar. 2024 )/Total Current Liabilities (Q: Mar. 2024 )
=1.009/8.516
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Provectus Biopharmaceuticals  (OTCPK:PVCT) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Provectus Biopharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
800 S Gay St, Suite 1610, Knoxville, TN, USA, 37932
Provectus Biopharmaceuticals Inc is a is a clinical-stage biotechnology company. It is engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The company has developed and intends to license or market and sell its two prescription drug candidates, PV-10 and PH-10. Its PV-10 is for the treatment of several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The PH-10 is to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema.
Executives
Jeffrey Allen Morris 10 percent owner 1729 TRIANGLE PARK DR., MARYVILLE TN 37801
Webster Bailey director 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Heather Raines officer: Chief Financial Officer 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Edward Pershing director 2220 SOUTHERLAND AVE, KNOXVILLE TN 37919
John Iii Lacy director 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
John R Glass officer: See Remarks 7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931
Bruce Horowitz director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Dominic Rodrigues director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Peter R Culpepper officer: Interim CEO, CFO, COO 7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931
Eric Phd Wachter director, officer: Chief Technology Officer PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Jan Koe director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Smith Alfred E. Iv director 191 MAIN STREET, NEW CANAAN CT 06840
Kelly M Mcmasters director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Donald E Adams 10 percent owner 370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401
Timothy Phd Scott director, 10 percent owner, officer: President PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931

Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Headlines

From GuruFocus

Provectus Biopharmaceuticals Releases 2023 Stockholder Letter

By Stock market mentor Stock market mentor 01-09-2023